Regenxbio (RGNX) Short-term Investments (2015 - 2025)

Regenxbio's Short-term Investments history runs 11 years deep, the most recent figure standing at $195.6 million for Q4 2025.

• On a quarterly basis, Short-term Investments rose 10.41% year-over-year to $195.6 million in Q4 2025; TTM through Dec 2025 was $195.6 million, a 10.41% increase from a year earlier, with the FY2025 full-year figure at $195.6 million, up 10.41% from the prior year.
• Short-term Investments retreated to $195.6 million in Q4 2025 per RGNX's latest filing, from $215.4 million in the prior quarter.
• Across five years, Short-term Investments topped out at $281.6 million in Q2 2022 and bottomed at $111.5 million in Q3 2021.
• The 5-year median for Short-term Investments is $220.6 million (2024), against an average of $206.8 million.
• Across the five-year window, Short-term Investments surged 139.31% in 2022 and sank 38.97% in 2025, its largest moves.
• Year by year, Short-term Investments stood at $112.2 million in 2021, then surged by 138.52% to $267.7 million in 2022, then fell by 10.07% to $240.7 million in 2023, then fell by 26.41% to $177.2 million in 2024, then climbed by 10.41% to $195.6 million in 2025.
• Per Business Quant, the three latest RGNX Short-term Investments figures stand at $195.6 million (Q4 2025), $215.4 million (Q3 2025), and $243.7 million (Q2 2025).